Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, CorMedix Inc’s stock clocked out at $11.67, up 1.13% from its previous closing price of $11.54. In other words, the price has increased by $1.13 from its previous closing price. On the day, 1.34 million shares were traded. CRMD stock price reached its highest trading level at $11.87 during the session, while it also had its lowest trading level at $11.5.
Ratios:
To gain a deeper understanding of CRMD’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.99 and its Current Ratio is at 4.21. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 30, 2025, initiated with a Buy rating and assigned the stock a target price of $20.
On March 07, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $18.Leerink Partners initiated its Outperform rating on March 07, 2025, with a $18 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 31 ’24 when Mistry Erin bought 1,500 shares for $9.99 per share. The transaction valued at 14,985 led to the insider holds 52,011 shares of the business.
Hurlburt Elizabeth sold 140,027 shares of CRMD for $1,565,670 on Nov 14 ’24. The EVP now owns 45,397 shares after completing the transaction at $11.18 per share. On Nov 14 ’24, another insider, Hurlburt Elizabeth, who serves as the Officer of the company, bought 140,027 shares for $11.12 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRMD now has a Market Capitalization of 868588800 and an Enterprise Value of 714487552. As of this moment, CorMedix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 51.77, and their Forward P/E ratio for the next fiscal year is 6.50. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.52 while its Price-to-Book (P/B) ratio in mrq is 6.88. Its current Enterprise Value per Revenue stands at 8.655 whereas that against EBITDA is 47.878.
Stock Price History:
The Beta on a monthly basis for CRMD is 1.70, which has changed by 1.7654028 over the last 52 weeks, in comparison to a change of 0.18569505 over the same period for the S&P500. Over the past 52 weeks, CRMD has reached a high of $17.43, while it has fallen to a 52-week low of $3.61. The 50-Day Moving Average of the stock is -7.51%, while the 200-Day Moving Average is calculated to be 9.89%.
Shares Statistics:
It appears that CRMD traded 2.14M shares on average per day over the past three months and 2271420 shares per day over the past ten days. A total of 74.43M shares are outstanding, with a floating share count of 72.39M. Insiders hold about 2.75% of the company’s shares, while institutions hold 32.27% stake in the company. Shares short for CRMD as of 1752537600 were 10049276 with a Short Ratio of 4.69, compared to 1749772800 on 8588351. Therefore, it implies a Short% of Shares Outstanding of 10049276 and a Short% of Float of 13.639999999999999.
Earnings Estimates
Current recommendations for the stock of the company come from 7.0 analysts. The consensus estimate for the next quarter is $0.24, with high estimates of $0.39 and low estimates of $0.08.
Analysts are recommending an EPS of between $1.73 and $0.53 for the fiscal current year, implying an average EPS of $1.07. EPS for the following year is $1.8, with 7.0 analysts recommending between $2.84 and $0.74.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $35.92M. It ranges from a high estimate of $37.49M to a low estimate of $31M. As of the current estimate, CorMedix Inc’s year-ago sales were $806.12kFor the next quarter, 6 analysts are estimating revenue of $42.46M. There is a high estimate of $49.4M for the next quarter, whereas the lowest estimate is $32M.
A total of 6 analysts have provided revenue estimates for CRMD’s current fiscal year. The highest revenue estimate was $205M, while the lowest revenue estimate was $135.08M, resulting in an average revenue estimate of $171.15M. In the same quarter a year ago, actual revenue was $43.47MBased on 7 analysts’ estimates, the company’s revenue will be $246.96M in the next fiscal year. The high estimate is $291.92M and the low estimate is $163.19M.
